Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
701 participants
OBSERVATIONAL
2023-07-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pan-canceR Early DetectIon projeCT (PREDICT)
NCT04817306
Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
NCT05343832
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies
NCT04835675
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
NCT05668910
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
NCT06544083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liver cancer arm
Participants with new diagnosis of liver cancer, from whom blood samples will be collected.
Liver-cancer early detection test
Blood collection and liver-cancer early detection test
Benign diseases arm
Participants with benign diseases of cancer, from whom blood samples will be collected.
Liver-cancer early detection test
Blood collection and liver-cancer early detection test
Healthy arm
Participants without known presence of malignancies or benign diseases of liver, from whom blood samples will be collected.
Liver-cancer early detection test
Blood collection and liver-cancer early detection test
Interfering cancer arm
Participants with new diagnosis of interfering cancer types, from whom blood samples will be collected.
Liver-cancer early detection test
Blood collection and liver-cancer early detection test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liver-cancer early detection test
Blood collection and liver-cancer early detection test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals capable of giving signed and legally effective informed consent voluntarily
* Individuals newly diagnosed with or suspected of having liver cancer (including hepatocellular carcinoma \[HCC\], intrahepatic cholangiocarcinoma \[ICC\], and combined hepatocellular-cholangiocarcinoma \[cHCC-CCA\]).
* Individuals without any anti-cancer therapy prior to blood sample collection.
* Individuals newly diagnosed as benign liver diseases before blood sample collection
* Individuals without curative treatment for the disease before blood sample collection
* Individuals diagnosed with or suspected of having interfering cancer
* Individuals without any anti-cancer therapy prior to blood sample collection
* No cancer-related or other clinical symptoms 30 days prior to blood sample collection
* No prior history of benign liver diseases
Exclusion Criteria
* Pregnancy or lactating women
* Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant
* Recipients of blood transfusion within 7 days prior to blood sample collection
* Recipients of anti-infective treatment within 14 days prior to blood sample collection
* Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer
* Individuals with a history of malignant tumor
* Known prior or current diagnosis of other types of malignancies or multiple primary cancers
* No confirmed diagnosis of liver cancer after blood sample collection
* Individuals with a confirmed diagnosis of a malignant tumor or precancerous lesion
* Individuals who cannot be diagnosed as having benign liver diseases after blood sample collection
* Known prior or current diagnosis of other types of malignancies or multiple primary cancers
* No confirmed diagnosis of any type of interfering cancers after blood sample collection
* Prior or ongoing treatment of cancers within 3 years prior to blood sample collection
* Clinically significant or uncontrolled comorbidities
18 Years
74 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Burning Rock Dx Co., Ltd.
INDUSTRY
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guoyue Lv
Professor of Gastroenterology & Hepatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tian Yang
Role: PRINCIPAL_INVESTIGATOR
Eastern Hepatobiliary Surgery Hospital
Nanya Wang
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Jilin University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jilin university first hospital
Changchun, Jilin, China
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bo Liu
Role: primary
Lanqing Yao
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSCD2022015P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.